Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173625 · ClinicalTrials.gov registry record · Phase 1
A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body
A Phase 1 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT03173625 is a Phase 1 study that has completed, run by Viatris Innovation. The registered enrollment target is 72 participants.
The verdict
NCT03173625, a Phase 1 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main objective of the study is to investigate the safety and tolerability of single ascending doses of AC-076 administered as subcutaneous injection
Interventions
- DRUG Placebo
- DRUG AC-076 for s.c. administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2017-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03173625
The ClinicalTrials.gov registry entry for NCT03173625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viatris Innovation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03173625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03173625 about?
NCT03173625 is a clinical study titled "A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body". The main objective of the study is to investigate the safety and tolerability of single ascending doses of AC-076 administered as subcutaneous injection
What is the current status of trial NCT03173625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-11-29. Estimated completion is 2017-04-15.
What interventions are being tested in trial NCT03173625?
The interventions under investigation include: Placebo (DRUG), AC-076 for s.c. administration (DRUG).
Who is sponsoring clinical trial NCT03173625?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.